Synthesis, cytostatic activity and ADME properties of C-5 substituted and N-acyclic pyrimidine derivatives

Kraljević, Tatjana Gazivoda; Klika, Mateja; Kralj, Marijeta; Martin-Kleiner, Irena; Jurmanović, Stella; Milić, Astrid; Padovan, Jasna; Raić‐Malić, Silvana

doi:10.1016/j.bmcl.2011.11.009

Cited by 22 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5-chloroethyl-2,6 dichloro pyrimidine 8 (IC 50 = 0.8 ± 0.2 μM) exerted cytostatic effect on HCT-116 cancer cell line which led to cell cycle arrest at G2/M phase due to DNA damage. The SAR suggests that the presence of two aromatic and an aliphatic chlorine atom linked to the pyrimidine ring gave the compound with maximum potential [11]. Furthermore, 2-arylaminopyrimidine derivative bearing a 2amino-N-methylbenzamide at C4 and chlorine at C5 positions were designed as a potent inhibitor of c-Met in cellular and enzymatic assays.…”

Section: 4 5-trisubstituted Pyrimidinesmentioning

confidence: 99%

Pyrimidine: a review on anticancer activity with key emphasis on SAR

2021

View full text Add to dashboard Cite

Background Cancer is a global health challenge, it impacts the quality of life and its treatment is associated with several side effects. Resistance of the cancer cells to the existing drugs has led to search for novel anticancer agents. Pyrimidine, a privileged scaffold, is part of living organisms and plays vital role in various biological procedures as well as in cancer pathogenesis. Due to resemblance in structure with the nucleotide base pair of DNA and RNA, it is recognized as valuable compound in the treatment of cancer. Main text Many novel pyrimidine derivatives have been designed and developed for their anticancer activity in the last few years. The present review aims to focus on the structure activity relationship (SAR) of pyrimidine derivatives as anticancer agent from the last decade. Conclusion This review intends to assist in the development of more potent and efficacious anticancer drugs with pyrimidine scaffold. Graphical abstract

show abstract

Section: 4 5-trisubstituted Pyrimidinesmentioning

confidence: 99%

Pyrimidine: a review on anticancer activity with key emphasis on SAR

2021

View full text Add to dashboard Cite

show abstract

“…The pyrimidine moiety, as one of the most important heterocyclic scaffolds, is considered a privileged structure in medicinal chemistry for drug discovery. 19,20 Pyrimidine derivatives have been reported to have a broad spectrum of biological activities, such as antiviral, 21,22 antibacterial, 23 antifungal, 24 anti-inammatory, 25,26 COX-2 inhibitors, 27 antituberculosis, 28 herbicidal 29 and insecticidal 30 activities. Moreover, previous studies have found that numerous pyrimidine derivatives exhibited promising anticancer activity.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and biological evaluation of dehydroabietic acid-pyrimidine hybrids as antitumor agents

Huang

Pang

et al. 2020

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…Pyrimidine ring is the building unit of DNA and RNA, due to which pyrimidine derivatives exhibit diverse pharmacological activities such as anticancer [2][3][4][5][6][7][8][9][10], antiviral [11][12][13] especially anti-HIV [14][15][16], antimalarial [17][18][19], antimicrobial [20,21] and anti-inflammatory [22,23]. They also exhibit activity against gonadotropin releasing hormone receptors and display herbicidal potential by inhibiting acetohydroxyacid synthase, a key enzyme in the biosynthesis of branched-chain amino acids [24][25][26].…”

Section: Introductionmentioning

confidence: 99%

Anti-Cancer Pyrimidines in Diverse Scaffolds: A Review of Patent Literature

Kaur

Sharma

et al. 2014

PRA

109

View full text Add to dashboard Cite

Pyrimidine ring is the building unit of DNA and RNA and thus pyrimidine based chemical architectures exhibit diverse pharmacological activities. Among the reported medicinal attributes of pyrimidines, anticancer activity is the most extensively reported. The anticancer potential of pyrimidines in fused scaffolds has also been evidenced through number of research article and patent literature. The pyrimidines based scaffolds have exerted their cell killing effects through varied mechanisms which indicate their potential to interact with diverse enzymes/ targets/receptors. This review article strictly focuses on the patent literature from 2009 onwards. The structure of the potent compounds, their IC50 values, models/assays used for the anticancer evaluation and the enzymes/ receptors/ targets involved have been presented in this compilation. Significant number of patents i.e. 59 have been published on pyrimidine based anticancer agents from 2009-2014 (from 2009 through the present date) which clearly indicate that this heterocycle is an area of focus at present for researchers all over the globe. Moreover, out of the 59 patents published during this period, 32 have been published from 2012 onwards which further highlights the present interest of the researcher towards pyrimidine based anticancer agents. The promising activity displayed by these pyrimidine based scaffolds clearly places them in forefront as potential future drug candidates. The present compilation can be extremely beneficial for the medicinal chemists working on design and synthesis of anticancer drugs.

show abstract

Synthesis, cytostatic activity and ADME properties of C-5 substituted and N-acyclic pyrimidine derivatives

Cited by 22 publications

References 27 publications

Pyrimidine: a review on anticancer activity with key emphasis on SAR

Pyrimidine: a review on anticancer activity with key emphasis on SAR

Synthesis and biological evaluation of dehydroabietic acid-pyrimidine hybrids as antitumor agents

Anti-Cancer Pyrimidines in Diverse Scaffolds: A Review of Patent Literature

Contact Info

Product

Resources

About